Trial Profile
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccines in Healthy Toddlers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2020
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 02 Mar 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 27 Mar 2015 New trial record